Dr Kathryn Taylor
Timau a rolau for Kathryn Taylor
Uwch Gymrawd Ymchwil Anrhydeddus
Trosolwyg
Trosolwg
Fy mhrif ffocws yw darganfod mecanweithiau signalau sinc mewn cyflwr iechyd a disesase. Mae gen i ffocws penodol ar rôl sinc mewn canser ond nid yn unig. Mae gen i hefyd ddiddordeb arbennig yn y teulu SLC39A o gludwyr sinc, gyda ffocws ar aelodau'r is-deulu LIV-1.
Ni oedd y cyntaf i ddarganfod is-deulu LIV-1 o gludwyr sinc oherwydd y motiff consensws unigryw y maent yn ei gynnwys.
Ni oedd y cyntaf i ddarganfod bod cludwyr sinc angen ffosfforyliad gan kinase i'w actifadu i allu cludo sinc. Fe wnaethom ddechrau hyn yn ZIP7, y prif gludwr sinc sy'n rhyddhau sinc i mewn i gelloedd o storfeydd cellualr, a oedd angen ffosfforyliad gan CK2 kinase er mwyn gallu cludo'r sinc a'i ryddhau o storfeydd. Galluogodd y darganfyddiad hwn gynhyrchu gwrthgorff unigryw sy'n adnabod ZIP7 yn unig yn ei gyflwr cludo sinc gweithredol. Rydym yn archwilio'r defnydd o'r gwrthgorff hwn i adnabod canserau sydd naill ai'n gwrthsefyll therapi neu'n dechrau tyfu gyda mwy o egni.
Ni oedd y cyntaf i ddarganfod y mecanwaith o sut mae sinc yn hanfodol ar gyfer rhannu celloedd. Mae angen i sinc fynd i mewn i gell trwy gludwyr sinc penodol cyn y gall y gell ddechrau rhannu. Gan ddefnyddio gwrthgorff penodol i'r moleciwl hwn, gallwn nawr atal y rhaniad celloedd hwn ac yn archwilio sut y gall hyn fod yn driniaeth canser usueful. Mae treialon anifeiliaid cyfredol wedi cadarnhau gallu'r gwrthgorff hwn i atal twf tiwmor yn effeithiol, ansawdd sy'n cael ei arsylwi mewn sawl math o ganser, gan gynnwys y rhai sy'n anodd neu'n amhosibl eu trin ar hyn o bryd.
Cymwysterau
- BSc (Anrhydedd) mewn Ffisioleg a Biocemeg, Prifysgol Reading, 1974
- PhD o Ysbyty Coleg y Brenin, Prifysgol Llundain mewn cadwraeth arennau 1982
Gwefannau perthnasol
- Grŵp Canser y Fron (Ffarmacoleg Moleciwlaidd)
- Zinc-UK - Cymdeithas ar gyfer gwyddonwyr sy'n ymwneud yn weithredol ag ymchwilio i sinc mewn bioleg yn y DU ac Ewrop.
- Cymdeithas Ryngwladol Bioleg Sinc - https://iszb.org/ - Y brif gymdeithas ryngwladol sy'n dwyn ynghyd wyddonwyr o amrywiaeth o feysydd sydd â diddordeb cyffredin yn agweddau strwythurol, biocemegol, genetig a ffisiolegol bioleg sinc
Cyrff cyllido sydd wedi cefnogi fy ymchwil
- Ymgyrch Canser y Fron
- Ymddiriedolaeth Wellcome
- Gofal Canser Tenovus - https://www.tenovuscancercare.org.uk/
- Rhwydwaith Ymchwil Gwyddorau Bywyd Cymru - http://www.lsrnw.ac.uk/
Cyhoeddiad
2025
- Rolles, B. et al., 2025. ZIP10 as a potential therapeutic target in acute myeloid leukaemia. British Journal of Haematology 207 (3), pp.767-779. (10.1111/bjh.20229)
- Alzahrani, A. M. and Taylor, K. M. 2025. Zinc transporters of the LIV-1 subfamily in various cancers: Molecular insights and research priorities for Saudi Arabia. International Journal of Molecular Sciences 26 (16) 8080. (10.3390/ijms26168080)
2023
- Farr, G. , Jones, S. and Taylor, K. M. 2023. Methods to visualise zinc transporter proteins of the SLC39A family in cells [Chapter 4]. In: Hu, J. ed. Methods in Enzymology. Vol. 687, Elsevier. , pp.67-85. (10.1016/bs.mie.2023.04.020)
- Taylor, K. M. 2023. The liv-1 subfamily of zinc transporters: from origins to present day discoveries. International Journal of Molecular Sciences 24 (2) 1255. (10.3390/ijms24021255)
2022
- Jones, S. et al. 2022. The importance of targeting signalling mechanisms of the SLC39A family of zinc transporters to inhibit endocrine resistant breast cancer. Exploration of Targeted Anti-tumor Therapy 3 , pp.224-239. (10.37349/etat.2022.00080)
2021
- Kambe, T. , Taylor, K. M. and Fu, D. 2021. Zinc transporters and their functional integration in mammalian cells. Journal of Biological Chemistry 296 100320. (10.1016/j.jbc.2021.100320)
2020
- Nimmanon, T. et al., 2020. The ZIP6/ZIP10 heteromer is essential for the zinc-mediated trigger of mitosis. Cellular and Molecular Life Sciences 78 , pp.1781-1798. (10.1007/s00018-020-03616-6)
- Suzuki, E. et al., 2020. Detailed analyses of the crucial functions of Zn transporter proteins in alkaline phosphatase activation. Journal of Biological Chemistry 295 , pp.5669-5684. (10.1074/jbc.RA120.012610)
2019
- Nimmanon, T. and Taylor, K. M. 2019. Post-translational mechanisms of zinc signalling in cancer. In: Fukada, T. and Kambe, T. eds. Zinc Signaling. Springer, Singapore. , pp.319-345. (10.1007/978-981-15-0557-7_16)
- Ziliotto, S. et al. 2019. Activated zinc transporter ZIP7 as an indicator of anti-hormone resistance in breast cancer. Metallomics 11 (9), pp.1579-1592. (10.1039/C9MT00136K)
- Mero, M. et al., 2019. ZnR/GPR39 upregulation of K+/Cl−-cotransporter 3 in tamoxifen resistant breast cancer cells. Cell Calcium 81 , pp.12-20. (10.1016/j.ceca.2019.05.005)
- Ollig, J. et al., 2019. B cell activation and proliferation increase intracellular zinc levels. Journal of Nutritional Biochemistry 64 , pp.72-79. (10.1016/j.jnutbio.2018.10.008)
2018
- Ventura-Bixenshpaner, H. et al., 2018. Enhanced ZnR/GPR39 activity in breast cancer, an alternative trigger of signaling leading to cell growth. Scientific Reports 8 (1) 8119. (10.1038/s41598-018-26459-5)
2017
- Nimmanon, T. et al., 2017. Phosphorylation of zinc channel ZIP7 drives MAPK, PI3K and mTOR growth and proliferation signalling. Metallomics 9 (5), pp.471-481. (10.1039/C6MT00286B)
- Tuncay, E. et al., 2017. Hyperglycemia-induced changes in ZIP7 and ZnT7 expression cause Zn2+ release from the sarco(endo)plasmic reticulum and mediate ER-stress in the heart. Diabetes 66 (5), pp.1346-1358. (10.2337/db16-1099)
2016
- Taylor, K. M. et al. 2016. Zinc transporter ZIP10 forms a heteromer with ZIP6 which regulates embryonic development and cell migration. Biochemical Journal 473 (16), pp.2531-2544. (10.1042/BCJ20160388)
- Hessels, A. M. , Taylor, K. M. and Merkx, M. 2016. Monitoring cytosolic and ER Zn2+ in stimulated breast cancer cells using genetically encoded FRET sensors. Metallomics 8 , pp.211-217. (10.1039/C5MT00257E)
2015
- Hessels, A. M. et al., 2015. eZinCh-2: a versatile, genetically encoded FRET sensor for cytosolic and intraorganelle Zn2+ imaging. ACS Chemical Biology 10 (9), pp.2126-2134. (10.1021/acschembio.5b00211)
- Liu, Y. et al., 2015. Characterization of Zinc Influx Transporters (ZIPs) in pancreatic beta cells: roles in regulating cytosolic zinc homeostasis and insulin secretion. Journal of Biological Chemistry 290 , pp.18757-18769. (10.1074/jbc.M115.640524)
- Wiggins, H. L. et al. 2015. Disulfiram-induced cytotoxicity and endo-lysosomal sequestration of zinc in breast cancer cells. Biochemical Pharmacology 93 (3), pp.332-342. (10.1016/j.bcp.2014.12.014)
2013
- Hogstrand, C. et al. 2013. A mechanism for epithelial–mesenchymal transition and anoikis resistance in breast cancer triggered by zinc channel ZIP6 and STAT3 (signal transducer and activator of transcription 3). Biochemical Journal 455 (2), pp.229-237. (10.1042/BJ20130483)
2012
- Taylor, K. M. , Kille, P. and Hogstrand, C. 2012. Protein kinase CK2 opens the gate for zinc signaling. Cell Cycle 11 (10), pp.1863-1864. (10.4161/cc.20414)
- Taylor, K. M. et al. 2012. Protein kinase CK2 triggers cytosolic zinc signaling pathways by phosphorylation of zinc channel ZIP7. Science Signaling 5 (210) ra11. (10.1126/scisignal.2002585)
2011
- Taylor, K. M. , Gee, J. M. W. and Kille, P. 2011. Zinc and cancer. In: Rink, L. ed. Zinc in Human Health. Biomedical and Health Research Vol. 76.Amsterdam: IOS Press. , pp.283-304.
- Taylor, K. M. et al. 2011. Differential subcellular localization of the splice variants of the zinc transporter ZnT5 is dictated by the different C-terminal regions. PLoS ONE 6 (8) e23878. (10.1371/journal.pone.0023878)
2010
- Thomas, N. B. P. et al., 2010. Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Research and Treatment 119 (3), pp.575-591. (10.1007/s10549-009-0355-8)
- Weaver, B. P. et al., 2010. Zip4 (Slc39a4) expression is activated in hepatocellular carcinomas and functions to repress apoptosis, enhance cell cycle and increase migration. PLoS ONE 5 (10) e13158. (10.1371/journal.pone.0013158)
2009
- Nicholson, R. I. et al. 2009. Experimental endocrine resistance: concepts and strategies. In: Hiscox, S. E. , Gee, J. M. W. and Nicholson, R. I. eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential. Dordrecht: Springer. , pp.1-26. (10.1007/978-1-4020-8526-0_1)
- Hiscox, S. E. et al. 2009. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Research and Treatment 115 (1), pp.57-67. (10.1007/s10549-008-0058-6)
- Hogstrand, C. et al., 2009. Zinc transporters and cancer: a potential role for ZIP7 as a hub for tyrosine kinase activation. Trends in Molecular Medicine 15 (3), pp.101-111. (10.1016/j.molmed.2009.01.004)
2008
- Taylor, K. M. et al. 2008. ZIP7-mediated intracellular zinc transport contributes to aberrant growth factor signaling in antihormone-resistant breast cancer cells. Endocrinology 149 (10), pp.4912-4920. (10.1210/en.2008-0351)
- Nicholson, R. I. et al. 2008. Compensatory signalling induced by anti-hormone and anti-growth factor therapies in breast cancer: a starting point for the development of resistance to targeted therapies.. In: Pasqualini, J. R. ed. Breast cancer: prognosis, treatment and prevention. 2nd ed. London: Informa Healthcare. , pp.123-136.
- Taylor, K. M. 2008. A distinct role in breast cancer for two LIV-1 family zinc transporters. Biochemical Society Transactions 36 (6), pp.1247-1251. (10.1042/bst0361247)
- Taylor, K. M. et al. 2008. Zinc transporter HKE4 as a new target in antihormone resistance of breast cancer [Abstract]. Breast Cancer Research 10 (s2) P42. (10.1186/bcr1926)
- Zahari, N. M. , Taylor, K. M. and Nicholson, R. I. 2008. Functional evaluation of members of the LIV-1 family of proteins and their role in breast cancer. EJC Supplements 6 (12), pp.184-184.
2007
- Taylor, K. M. et al. 2007. The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer. Molecular Medicine 13 (7-8), pp.396-406.
- Nicholson, R. I. et al. 2007. Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. Reviews in Endocrine and Metabolic Disorders 8 (3), pp.241-253. (10.1007/s11154-007-9033-5)
2006
- Hiscox, S. E. et al. 2006. Tamoxifen-resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of [beta]-catenin phosphorylation. International journal of cancer 118 (2), pp.290-301. (10.1002/ijc.21355)
2005
- Jones, H. E. et al. 2005. Development of strategies for the use of anti-growth factor treatments. Endocrine-Related Cancer 12 (S1), pp.S173-S182. (10.1677/erc.1.01004)
- Taylor, K. M. et al. 2005. Zinc-dependant stimulation of Src, EGFR and IGFR signalling pathways in tamoxifen-resistant breast cancer and the role of zinc transporters. Breast Cancer Research and Treatment 94 (Supp 1), pp.S162-S162.
2004
- Taylor, K. M. et al. 2004. Structure-function analysis of HKE4, a member of the new LIV-1 subfamily of zinc transporters. Biochemical Journal 377 (1), pp.131-139. (10.1042/BJ20031183)
- Taylor, K. M. , Hiscox, S. E. and Nicholson, R. 2004. Zinc transporter LIV-1: a link between cellular development and cancer progression. Trends in Endocrinology and Metabolism 15 (10), pp.461-463.
2003
- Taylor, K. M. et al. 2003. Structure-function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of zinc transporters. Biochemical Journal 375 (1), pp.51-59. (10.1042/BJ20030478)
2001
- Glynne-Jones, E. M. et al., 2001. TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence. International Journal of Cancer 94 (2), pp.178-184. (10.1002/ijc.1450)
2000
- Dunstan, S. L. et al., 2000. Cloning and expression of the bioluminescent photoprotein pholasin from the bivalve mollusc Pholas dactylus. Journal of Biological Chemistry 275 (13), pp.9403-9409. (10.1074/jbc.275.13.9403)
1998
- Sala-Newby, G. B. et al., 1998. Imaging bioluminescent indicators shows Ca2+ and ATP permeability thresholds in live cells attacked by complement. Immunology 93 (4), pp.601-609. (10.1046/j.1365-2567.1998.00004.x)
1997
- Taylor, K. M. , Trimby, A. R. and Campbell, A. K. 1997. Mutation of recombinant complement component C9 reveals the significance of the N-terminal region for polymerization. Immunology 91 (1), pp.20-27. (10.1046/j.1365-2567.1997.00225.x)
1994
- Taylor, K. M. , Luzio, J. P. and Campbell, A. K. 1994. A method for in vitro synthesis of unglycosylated recombinant complement component C9. Journal of Immunological Methods 167 (1-2), pp.129-137. (10.1016/0022-1759(94)90082-5)
- Taylor, K. M. , Morgan, B. P. and Campbell, A. K. 1994. Altered glycosylation and selected mutation in recombinant human complement component C9: effects on haemolytic activity. Immunology 83 (3), pp.501-506.
Adrannau llyfrau
- Farr, G. , Jones, S. and Taylor, K. M. 2023. Methods to visualise zinc transporter proteins of the SLC39A family in cells [Chapter 4]. In: Hu, J. ed. Methods in Enzymology. Vol. 687, Elsevier. , pp.67-85. (10.1016/bs.mie.2023.04.020)
- Nimmanon, T. and Taylor, K. M. 2019. Post-translational mechanisms of zinc signalling in cancer. In: Fukada, T. and Kambe, T. eds. Zinc Signaling. Springer, Singapore. , pp.319-345. (10.1007/978-981-15-0557-7_16)
- Taylor, K. M. , Gee, J. M. W. and Kille, P. 2011. Zinc and cancer. In: Rink, L. ed. Zinc in Human Health. Biomedical and Health Research Vol. 76.Amsterdam: IOS Press. , pp.283-304.
- Nicholson, R. I. et al. 2009. Experimental endocrine resistance: concepts and strategies. In: Hiscox, S. E. , Gee, J. M. W. and Nicholson, R. I. eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential. Dordrecht: Springer. , pp.1-26. (10.1007/978-1-4020-8526-0_1)
- Nicholson, R. I. et al. 2008. Compensatory signalling induced by anti-hormone and anti-growth factor therapies in breast cancer: a starting point for the development of resistance to targeted therapies.. In: Pasqualini, J. R. ed. Breast cancer: prognosis, treatment and prevention. 2nd ed. London: Informa Healthcare. , pp.123-136.
Erthyglau
- Rolles, B. et al., 2025. ZIP10 as a potential therapeutic target in acute myeloid leukaemia. British Journal of Haematology 207 (3), pp.767-779. (10.1111/bjh.20229)
- Alzahrani, A. M. and Taylor, K. M. 2025. Zinc transporters of the LIV-1 subfamily in various cancers: Molecular insights and research priorities for Saudi Arabia. International Journal of Molecular Sciences 26 (16) 8080. (10.3390/ijms26168080)
- Taylor, K. M. 2023. The liv-1 subfamily of zinc transporters: from origins to present day discoveries. International Journal of Molecular Sciences 24 (2) 1255. (10.3390/ijms24021255)
- Jones, S. et al. 2022. The importance of targeting signalling mechanisms of the SLC39A family of zinc transporters to inhibit endocrine resistant breast cancer. Exploration of Targeted Anti-tumor Therapy 3 , pp.224-239. (10.37349/etat.2022.00080)
- Kambe, T. , Taylor, K. M. and Fu, D. 2021. Zinc transporters and their functional integration in mammalian cells. Journal of Biological Chemistry 296 100320. (10.1016/j.jbc.2021.100320)
- Nimmanon, T. et al., 2020. The ZIP6/ZIP10 heteromer is essential for the zinc-mediated trigger of mitosis. Cellular and Molecular Life Sciences 78 , pp.1781-1798. (10.1007/s00018-020-03616-6)
- Suzuki, E. et al., 2020. Detailed analyses of the crucial functions of Zn transporter proteins in alkaline phosphatase activation. Journal of Biological Chemistry 295 , pp.5669-5684. (10.1074/jbc.RA120.012610)
- Ziliotto, S. et al. 2019. Activated zinc transporter ZIP7 as an indicator of anti-hormone resistance in breast cancer. Metallomics 11 (9), pp.1579-1592. (10.1039/C9MT00136K)
- Mero, M. et al., 2019. ZnR/GPR39 upregulation of K+/Cl−-cotransporter 3 in tamoxifen resistant breast cancer cells. Cell Calcium 81 , pp.12-20. (10.1016/j.ceca.2019.05.005)
- Ollig, J. et al., 2019. B cell activation and proliferation increase intracellular zinc levels. Journal of Nutritional Biochemistry 64 , pp.72-79. (10.1016/j.jnutbio.2018.10.008)
- Ventura-Bixenshpaner, H. et al., 2018. Enhanced ZnR/GPR39 activity in breast cancer, an alternative trigger of signaling leading to cell growth. Scientific Reports 8 (1) 8119. (10.1038/s41598-018-26459-5)
- Nimmanon, T. et al., 2017. Phosphorylation of zinc channel ZIP7 drives MAPK, PI3K and mTOR growth and proliferation signalling. Metallomics 9 (5), pp.471-481. (10.1039/C6MT00286B)
- Tuncay, E. et al., 2017. Hyperglycemia-induced changes in ZIP7 and ZnT7 expression cause Zn2+ release from the sarco(endo)plasmic reticulum and mediate ER-stress in the heart. Diabetes 66 (5), pp.1346-1358. (10.2337/db16-1099)
- Taylor, K. M. et al. 2016. Zinc transporter ZIP10 forms a heteromer with ZIP6 which regulates embryonic development and cell migration. Biochemical Journal 473 (16), pp.2531-2544. (10.1042/BCJ20160388)
- Hessels, A. M. , Taylor, K. M. and Merkx, M. 2016. Monitoring cytosolic and ER Zn2+ in stimulated breast cancer cells using genetically encoded FRET sensors. Metallomics 8 , pp.211-217. (10.1039/C5MT00257E)
- Hessels, A. M. et al., 2015. eZinCh-2: a versatile, genetically encoded FRET sensor for cytosolic and intraorganelle Zn2+ imaging. ACS Chemical Biology 10 (9), pp.2126-2134. (10.1021/acschembio.5b00211)
- Liu, Y. et al., 2015. Characterization of Zinc Influx Transporters (ZIPs) in pancreatic beta cells: roles in regulating cytosolic zinc homeostasis and insulin secretion. Journal of Biological Chemistry 290 , pp.18757-18769. (10.1074/jbc.M115.640524)
- Wiggins, H. L. et al. 2015. Disulfiram-induced cytotoxicity and endo-lysosomal sequestration of zinc in breast cancer cells. Biochemical Pharmacology 93 (3), pp.332-342. (10.1016/j.bcp.2014.12.014)
- Hogstrand, C. et al. 2013. A mechanism for epithelial–mesenchymal transition and anoikis resistance in breast cancer triggered by zinc channel ZIP6 and STAT3 (signal transducer and activator of transcription 3). Biochemical Journal 455 (2), pp.229-237. (10.1042/BJ20130483)
- Taylor, K. M. , Kille, P. and Hogstrand, C. 2012. Protein kinase CK2 opens the gate for zinc signaling. Cell Cycle 11 (10), pp.1863-1864. (10.4161/cc.20414)
- Taylor, K. M. et al. 2012. Protein kinase CK2 triggers cytosolic zinc signaling pathways by phosphorylation of zinc channel ZIP7. Science Signaling 5 (210) ra11. (10.1126/scisignal.2002585)
- Taylor, K. M. et al. 2011. Differential subcellular localization of the splice variants of the zinc transporter ZnT5 is dictated by the different C-terminal regions. PLoS ONE 6 (8) e23878. (10.1371/journal.pone.0023878)
- Thomas, N. B. P. et al., 2010. Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Research and Treatment 119 (3), pp.575-591. (10.1007/s10549-009-0355-8)
- Weaver, B. P. et al., 2010. Zip4 (Slc39a4) expression is activated in hepatocellular carcinomas and functions to repress apoptosis, enhance cell cycle and increase migration. PLoS ONE 5 (10) e13158. (10.1371/journal.pone.0013158)
- Hiscox, S. E. et al. 2009. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Research and Treatment 115 (1), pp.57-67. (10.1007/s10549-008-0058-6)
- Hogstrand, C. et al., 2009. Zinc transporters and cancer: a potential role for ZIP7 as a hub for tyrosine kinase activation. Trends in Molecular Medicine 15 (3), pp.101-111. (10.1016/j.molmed.2009.01.004)
- Taylor, K. M. et al. 2008. ZIP7-mediated intracellular zinc transport contributes to aberrant growth factor signaling in antihormone-resistant breast cancer cells. Endocrinology 149 (10), pp.4912-4920. (10.1210/en.2008-0351)
- Taylor, K. M. 2008. A distinct role in breast cancer for two LIV-1 family zinc transporters. Biochemical Society Transactions 36 (6), pp.1247-1251. (10.1042/bst0361247)
- Taylor, K. M. et al. 2008. Zinc transporter HKE4 as a new target in antihormone resistance of breast cancer [Abstract]. Breast Cancer Research 10 (s2) P42. (10.1186/bcr1926)
- Zahari, N. M. , Taylor, K. M. and Nicholson, R. I. 2008. Functional evaluation of members of the LIV-1 family of proteins and their role in breast cancer. EJC Supplements 6 (12), pp.184-184.
- Taylor, K. M. et al. 2007. The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer. Molecular Medicine 13 (7-8), pp.396-406.
- Nicholson, R. I. et al. 2007. Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. Reviews in Endocrine and Metabolic Disorders 8 (3), pp.241-253. (10.1007/s11154-007-9033-5)
- Hiscox, S. E. et al. 2006. Tamoxifen-resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of [beta]-catenin phosphorylation. International journal of cancer 118 (2), pp.290-301. (10.1002/ijc.21355)
- Jones, H. E. et al. 2005. Development of strategies for the use of anti-growth factor treatments. Endocrine-Related Cancer 12 (S1), pp.S173-S182. (10.1677/erc.1.01004)
- Taylor, K. M. et al. 2005. Zinc-dependant stimulation of Src, EGFR and IGFR signalling pathways in tamoxifen-resistant breast cancer and the role of zinc transporters. Breast Cancer Research and Treatment 94 (Supp 1), pp.S162-S162.
- Taylor, K. M. et al. 2004. Structure-function analysis of HKE4, a member of the new LIV-1 subfamily of zinc transporters. Biochemical Journal 377 (1), pp.131-139. (10.1042/BJ20031183)
- Taylor, K. M. , Hiscox, S. E. and Nicholson, R. 2004. Zinc transporter LIV-1: a link between cellular development and cancer progression. Trends in Endocrinology and Metabolism 15 (10), pp.461-463.
- Taylor, K. M. et al. 2003. Structure-function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of zinc transporters. Biochemical Journal 375 (1), pp.51-59. (10.1042/BJ20030478)
- Glynne-Jones, E. M. et al., 2001. TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence. International Journal of Cancer 94 (2), pp.178-184. (10.1002/ijc.1450)
- Dunstan, S. L. et al., 2000. Cloning and expression of the bioluminescent photoprotein pholasin from the bivalve mollusc Pholas dactylus. Journal of Biological Chemistry 275 (13), pp.9403-9409. (10.1074/jbc.275.13.9403)
- Sala-Newby, G. B. et al., 1998. Imaging bioluminescent indicators shows Ca2+ and ATP permeability thresholds in live cells attacked by complement. Immunology 93 (4), pp.601-609. (10.1046/j.1365-2567.1998.00004.x)
- Taylor, K. M. , Trimby, A. R. and Campbell, A. K. 1997. Mutation of recombinant complement component C9 reveals the significance of the N-terminal region for polymerization. Immunology 91 (1), pp.20-27. (10.1046/j.1365-2567.1997.00225.x)
- Taylor, K. M. , Luzio, J. P. and Campbell, A. K. 1994. A method for in vitro synthesis of unglycosylated recombinant complement component C9. Journal of Immunological Methods 167 (1-2), pp.129-137. (10.1016/0022-1759(94)90082-5)
- Taylor, K. M. , Morgan, B. P. and Campbell, A. K. 1994. Altered glycosylation and selected mutation in recombinant human complement component C9: effects on haemolytic activity. Immunology 83 (3), pp.501-506.
Ymchwil
Aelod o Ddisgyblaeth Ymchwil Ffarmacoleg a Ffisioleg yr Ysgol.
Diddordebau ymchwil
- Mecanwaith gweithredu cludwyr sinc
- Rheoleiddio homeostasis sinc mewngellog
- Rôl cludwyr sinc mewn mudo celloedd
- Rôl cludwyr sinc a sinc mewn dilyniant canser
- Rôl cludwyr sinc wrth gychwyn rhannu celloedd
Fy mhrif ffocws yw ymchwilio i fecanwaith gweithredu cludwyr sinc cellog, yn enwedig y teulu ZIP (a elwir hefyd yn SLC39A). Y bwriad yw cadarnhau model ar gyfer signalau sinc integredig mewn celloedd, gan gadarnhau rôl allweddol cludwyr sinc, yn enwedig ZIP7, a chysylltu'r canfyddiadau ag effeithiau biolegol sylfaenol sinc cellog. Credir bod y digwyddiadau signalau sinc hyn yn cael eu rheoli'n bennaf gan gludwyr sinc penodol neu sianeli a bydd fy nghanfyddiad newydd diweddar y gellir rheoli eu gallu cludo sinc trwy ffosfforyliad, mecanwaith blaenorol digynsail ar gyfer cludwyr sinc, yn cael ei archwilio ar gyfer perthynas strwythurol a / neu swyddogaethol uniongyrchol â llwybrau signalau cellog. Mae'r digwyddiadau hyn yn arwain at effeithiau cellog amrywiol ar brosesau arferol fel twf, datblygiad a mudo neu, pan fyddant yn cael eu rheoleiddio'n aberrantly, clefydau fel canser, diabetes a niwroddirywiad gan sicrhau bod y prosiect hwn yn cael cymhwysiad eang ar gyfer cyflyrau normal a chlefydau.
Prif ffocws fy ymchwil yw deall sut mae cludwyr sinc yn gweithio mewn celloedd i reoli homeostasis sinc mewngellog. Mae gen i ddiddordeb arbennig yn y 9 aelod dynol o'r teulu LIV-1 o gludwyr sinc a'u rôl yn y dilyniant o ganser y fron. Mae'r astudiaethau hyn yn cynnwys effeithiau sinc ar lwybrau signalau lluosog yn ogystal â thwf a goresgyniad, pob elfen y gwyddys eu bod yn arwain at ddilyniant canser. Gellir sicrhau hyn trwy ddefnyddio araeau ffosffo-kinase ar y cyd â mwtagenesis cludwyr sinc.
Trin sinc mewn celloedd
Mae dau deulu o gludwyr sinc yn galluogi sinc i groesi pilenni biolegol: Y teulu ZnT o gludwyr fflwcs sinc (a elwir yn SLC30A) a'r teulu ZIP o gludwyr mewnlifiad sinc (a elwir yn SLC39A). Mae'r teulu ZIP o gludwyr sinc yn cynhyrchu sinc cytosolig labile ac felly dangoswyd bod ganddynt rolau biolegol eang mewn cyflwr normal a chlefyd. Mae cludwr sinc ZIP7, sy'n unigryw ymhlith cludwyr ZIP, wedi'i leoli ar y bilen ER ac rydym wedi cynnig rôl reoli ar gyfer ZIP7 yn ddiweddar wrth ryddhau sinc o storfeydd mewngellog sy'n arwain at actifadu tyrosin kinases lluosog trwy anactifadu ffosffasau protein wedi'u cyfryngu gan sinc. Rydym wedi dangos bod ZIP7 yn gofyn am phopshorylation cyn y gall gludo sinc a gweithredu fel canolbwynt ar gyfer rhyddhau sinc o siopau.
Mecanwaith gweithredu'r teulu LIV-1 o gludwyr sinc
Gan ddefnyddio meddalwedd cyfrifiadurol i gymharu dilyniannau protein, roeddwn yn gallu dangos bod LIV-1 yn perthyn i deulu newydd o gludwyr mewnlifiad sinc sy'n gyfanswm o naw aelod o'r teulu dynol. Roedd chwiliadau cyfrifiadurol o strwythur eilaidd yn rhagweld bod y moleciwlau hyn yn cynnwys 8 parth trawsbilen, N-derfyn allgellog hir, C-derfyn allgellog byr, dilyniant consensws ar gyfer y teulu ZIP o gludwyr sinc a dilyniant consensws ar gyfer safle rhwymo sinc catalytig metalloproteases, (HEXXH, lle H = histidine, E = asid glutamig a X = unrhyw asid amino). Roedd y motiff olaf hwn yn anarferol gan ei fod hefyd yn cynnwys dau weddillion newydd (HEXPHE), proline (P) ac asid glutamig (E), cyn hynny yn y safleoedd hyn mewn unrhyw fotiffau metalloprotease eraill. Wrth chwilio'r gronfa ddata NCBI nad yw'n ddiangen gan ddefnyddio BLAST a'r motiff unigryw HEXPHEXGD o LIV-1, rydym wedi nodi dros 39 o ddilyniannau o 12 rhywogaeth, gan gynnwys dynol, llygoden, C.elegans, Drosophila, burum a bacteria, sy'n cynnwys y motiff unigryw a chadwredig iawn hwn. Mae'r teulu hwn bellach wedi'i alw'n SLC39A. Mae aelodau'r is-deulu LIV-1 yn debyg i gludwyr uwch-deulu ZIP o ran strwythur eilaidd a'r gallu i gludo ïonau metel ar draws y bilen plasma neu bilenni mewngellog. Mae lleoleiddio rhai aelodau'r teulu i lamellipodiae yn adlewyrchu lleoliad cellog y metalloproteases matrics math pilen. Gall y gwahaniaethau hyn i gludwyr sinc eraill fod yn gyson â rôl amgen iddynt mewn celloedd, yn enwedig mewn clefydau fel canser.
Rôl cludwyr sinc mewn iechyd a chlefydau
Mae'r 9 aelod dynol o'r teulu LIV-1 o gludwyr sinc yn cael eu cysylltu'n fwyfwy ag amrywiaeth o gyflyrau clefyd, yn enwedig niwroddirywiad, asthma, canser y prostad a chanser y fron. Mae ymchwilio i sut y gall lleoleiddio cellog a phenodoldeb meinwe y cludwyr sinc hyn newid homeostasis sinc yn hollbwysig i ddeall union rôl y cludwyr hyn yn y gwahanol gyflyrau clefyd hyn.
Rôl cludwyr sinc mewn mudo celloedd a mitosis
Mae ZIP6 (neu LIV-1 fel y'i gelwid) yn genyn a reolir gan estrogen sydd wedi'i gysylltu â chanser y fron metastatig. Mae ei ganfod wedi bod yn gysylltiedig â chanser y fron positif derbynnydd estrogen a lledaeniad metastatig y canserau hyn i'r nodau lymff rhanbarthol. Rydym wedi dangos rôl i ZIP6 a ZIP10 wrth hyrwyddo mudo celloedd ac rydym bellach wedi ymestyn hyn i ddeall y rôl y maent yn ei chwarae wrth gychwyn mitosis. Mae'r darganfyddiad hwn wedi galluogi ymchwil gan ddefnyddio gwrthgyrff ZIP unigryw i atal neu arafu twf canser.
Rôl cludwyr sinc a sinc mewn canser y fron
Rydym wedi arsylwi lefel uwch o sinc mewngellog yn ein model 'mewnol' o ganser y fron sy'n gwrthsefyll tamoxifen. Mae hyn wedi cychwyn ymchwiliad i rôl bosibl sinc yn actifadu llwybrau signalau a welir yn y celloedd hyn yn ogystal â'r cynnydd mewn ymddygiad ymosodol a welir yn y celloedd hyn. Trwy'r invetsigation hwn rydym wedi dangos rôl bwysig ar gyfer cludwr sinc ZIP7 wrth yrru twf ac actifadu canserau y fron sy'n gwrthsefyll tamoxifen. Mae ein darganfyddiad bod ZIP7 yn gofyn am ffosfforyliad cyn y gall ryddhau sinc o siopau wedi caniatáu inni gynhyrchu gwrthgorff ffosffo-ZIP7 unigryw sy'n cydnabod ZIP7 dim ond pan fydd yn rhyddhau sinc o siopau. Mae gan y gwrthgorff hwn lawer o botensial ar gyfer defnydd clinigol gan fod ei weithgaredd wedi'i alinio â mwy o dwf ac amlhau celloedd.
Y darganfyddiad bod ZIP6 a ZIP10 yn cychwyn rhannu celloedd
Mae ZIP6 a ZIP10 bob amser wedi bod yn anodd eu hastudio oherwydd eu lefel uchel o reoleiddio mewn celloedd. Fodd bynnag, rydym bellach wedi darganfod y rheswm am hyn. Mae ZIP6 a ZIP10 yn ffurfio cymhleth sy'n symud i'r gell allan pan fydd y gell yn barod i rannu celloedd. Mae'r cymhleth hwn yn dod â sinc i'r gell ac mae gan sinc swyddogaeth arbenigol iawn i sbarduno'r llwybrau arferol o mitosis. Heb y mewnlifiad sinc hwn, nid yw rhannu celloedd yn digwydd. Rydym bellach wedi ehangu ar y canlyniad hwn a chynhyrchu rhai gwrthgyrff newydd a all atal y mewnlifiad sinc a thrwy hynny atal rhannu celloedd sydd bellach yn cael eu harchwilio fel triniaeth canser newydd.
Cydweithwyr
Prifysgol Caerdydd
- Dr. Julia Gee, Ysgol Fferylliaeth a Gwyddorau Fferyllol, Prifysgol Caerdydd
- Yr Athro Richard Clarkson, Ysgol y Biowyddorau, Prifysgol Caerdydd
DU
- Yr Athro Christer Hogstrand, Coleg y Brenin, Llundain
- Yr Athro Wolfgang Maret, Coleg y Brenin, Llundain
- Yr Athro Iain Ellis, Gwyddorau Meddygol Moleciwlaidd, Ysbyty y Ddinas, Nottingham: cydweithredu ar gyfres canser y fron clinigol
- Yr Athro John Robertson, Ysbyty y Ddinas, Nottingham: cydweithio ar gyfres glinigol canser y fron
Rhyngwladol
- Yr Athro Glen Andrews, Adran Biocemeg a Bioleg Moleciwlaidd, Canolfan Feddygol Prifysgol Kansas, Kansas, UDA
- Yr Athro Michal Hershfinkel, Israel
- Yr Athro Lothar Rink, Aachen, Yr Almaen
- Yr Athro Gerold Schmitt-Ulms, Toronto, Canada
Technolegau a ddefnyddiwyd
- Adeiladau peirianneg ar gyfer mynegiant proteinau ailgyfunol mewn celloedd mamaliaid gan ddefnyddio clonio TOPO-TA a PCR.
- Knockdown mynegiant protein gan ddefnyddio siRNA
- Cynhyrchu mwtaniaid gan ddefnyddio mwtagenesis wedi'i gyfeirio at y safle a dilyniannu genynnau i alluogi ymchwilio i weddillion allweddol mewn gweithgaredd swyddogaethol gwahanol foleciwlau
- Defnyddio tagiau ar gyfer monitro mynegiant proteinau ailgyfunol mewn celloedd
- Defnyddio llinellau celloedd knockout a gynhyrchir gan ddefnyddio technoleg crispr
- Microsgopeg fflwroleuol a chonffocal o chwiliedydd lluosog mewn celloedd byw a sefydlog
- Assay Ligation Agosrwydd
- Dadansoddiad arae ffosffo-kinase
- Monitro amser real o grynodiadau Zn2 + mewn celloedd gan ddefnyddio gwahanol ddangosyddion sinc penodol fel Newport Green, Fluozin-3 a Zinquin.
- Dylunio a chynhyrchu gwrthgyrff newydd i broteinau cludwr sinc
- SDS-PAGE, Western Blotting, dadansoddiad FACS, imiwnocytocemeg.
- Defnyddio meddalwedd cyfrifiadurol i ragweld swyddogaeth protein
- Defnyddio cronfeydd data canser i ymchwilio i rôl cludwyr sinc
Addysgu
Mae Kathryn wedi dysgu ar bob modiwl o'r MSc mewn Bioleg a Therapiwteg Celloedd Canser ac mae ganddi brofiad sylweddol o oruchwylio prosiectau myfyrwyr mewn labordy
- PHT801 MSc Bioleg a Therapiwteg Celloedd Canser
- PHT802 MSc Bioleg a Therapiwteg Celloedd Canser
- PHT803 MSc Bioleg a Therapiwteg Celloedd Canser
- PHT804 MSc Bioleg a Therapiwteg Celloedd Canser
- PHT805 MSc Bioleg a Therapiwteg Celloedd Canser
- PHT806 MSc Bioleg a Therapiwteg Celloedd Canser
- Arweinydd modiwl ar gyfer PHT804
- Goruchwylio prosiectau ymchwil israddedig MPharm
- Goruchwylio myfyrwyr PhD ôl-raddedig
- Goruchwylio myfyrwyr PTY israddedig
- Goruchwylio myfyrwyr Erasmus
- Goruchwylio prosiectau myfyrwyr ymchwil MSc ôl-raddedig
Bywgraffiad
Proffil gyrfa
Astudiodd Kathryn Taylor ar gyfer PhD ym maes cadwraeth arennau ar gyfer trawsblannu yn yr adran lawfeddygaeth yn Ysbyty Coleg y Brenin, Denmark Hill, Llundain.
Ar ôl seibiant gyrfa 9 mlynedd i'r fam, dychwelodd i ymchwilio i rôl cydran ategol C9 mewn arthritis yn yr adran Biocemeg Feddygol, Ysbyty Mynydd Bychan, Caerdydd.
Ymunodd Kathryn â Chanolfan Ymchwil Canser Tenovus ym 1997 lle mae hi wedi bod yn ymchwilio i rôl y teulu LIV-1 o gludwyr sinc mewn canser y fron.
Symudodd Kathryn i'r Ysgol Fferylliaeth a Gwyddorau Fferyllol gydag Uned Tenovus yn 2000 ac mae'n dal i fod yno.
Dyfarnwyd cymrodoriaeth Prifysgol Ymddiriedolaeth Wellcome i Kathryn rhwng 2010 a 2015 a helpodd i gadarnhau ei diddordeb mewn cludwyr sinc, yn enwedig ZIP7, ZIP6 a ZIP10.
Yn 2015, cyflogwyd Kathryn fel Uwch Ddarlithydd yn yr Ysgol Fferylliaeth a Gwyddorau Fferyllol, lle dechreuodd ddysgu ar yr MSc mewn Bioleg a Therapiwteg Celloedd Canser.
Anrhydeddau a dyfarniadau
- Dyfarnwyd gwobr Fredericksen am ragoriaeth mewn bioleg sinc gan y Gymdeithas Ryngwladol ar gyfer Bioleg Sinc yn 2022
- Etholwyd yn Gyn-Lywydd y Gymdeithas Ryngwladol ar gyfer Bioleg Sinc (ISZB) 2019-2021
- Etholwyd yn Llywydd y Gymdeithas Ryngwladol ar gyfer Bioleg Sinc (ISZB) 2017-2019
- Aelod o fwrdd y Gymdeithas Ryngwladol ar gyfer Bioleg Sinc (ISZB) 2013-2017
Aelodaethau proffesiynol
- Yn aelod cyntaf o'r Gymdeithas Ryngwladol ar gyfer Bioleg Sinc ers 2007
- Aelod gwahoddedig o banel cynghori golygyddol y Biochemistry Journal 2004-2010
- Yn aelod o'r Gymdeithas Biocemegol ers 2002
Pwyllgorau ac adolygu
Adolygydd cyfnodolion a grant ar gyfer cyfnodolion lluosog
Meysydd goruchwyliaeth
Goruchwyliaeth gyfredol
Georgia Farr
Contact Details
+44 29208 75292
Adeilad Redwood , Llawr 2, Ystafell 2.32, Rhodfa'r Brenin Edward VII, Caerdydd, CF10 3NB
Themâu ymchwil
Arbenigeddau
- Cludwyr sinc
- Oncoleg a charsinogenesis
- Mitosis